Huntington's disease: seeing the pathogenic process through a genetic lens
- PMID: 16829072
- DOI: 10.1016/j.tibs.2006.06.009
Huntington's disease: seeing the pathogenic process through a genetic lens
Abstract
Thirteen years ago, the culmination of genetic rather than biochemical strategies resulted in the identification of the root cause of Huntington's disease: an expanded CAG trinucleotide repeat that leads to an elongated polyglutamine tract in the huntingtin protein. Since then, biochemical and cell biological attempts to elucidate pathogenesis have largely focused on N-terminal polyglutamine-containing huntingtin fragments. However, continued application of genetic strategies has suggested that the disease process is, in fact, triggered by the presence of expanded polyglutamine in intact huntingtin. An increased emphasis on the earliest presymptomatic stages of the disease, facilitated by incorporating genetic lessons from human patients into the search for biochemical targets, could provide a route to a rational treatment to prevent or slow the onset of this devastating neurodegenerative disorder.
Similar articles
-
Huntingtin-protein interactions and the pathogenesis of Huntington's disease.Trends Genet. 2004 Mar;20(3):146-54. doi: 10.1016/j.tig.2004.01.008. Trends Genet. 2004. PMID: 15036808 Review.
-
Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.J Neurosci Res. 2010 Jan;88(1):179-90. doi: 10.1002/jnr.22184. J Neurosci Res. 2010. PMID: 19642201
-
Huntington's disease: from molecular pathogenesis to clinical treatment.Lancet Neurol. 2011 Jan;10(1):83-98. doi: 10.1016/S1474-4422(10)70245-3. Lancet Neurol. 2011. PMID: 21163446 Review.
-
Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.Prog Neurobiol. 2007 Nov;83(4):211-27. doi: 10.1016/j.pneurobio.2006.11.004. Epub 2007 Jan 22. Prog Neurobiol. 2007. PMID: 17240517 Review.
-
Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.J Neurochem. 2008 Feb;104(3):846-58. doi: 10.1111/j.1471-4159.2007.05032.x. Epub 2007 Nov 6. J Neurochem. 2008. PMID: 17986219
Cited by
-
HSP90 recognizes the N-terminus of huntingtin involved in regulation of huntingtin aggregation by USP19.Sci Rep. 2017 Nov 1;7(1):14797. doi: 10.1038/s41598-017-13711-7. Sci Rep. 2017. PMID: 29093475 Free PMC article.
-
Formation and toxicity of soluble polyglutamine oligomers in living cells.PLoS One. 2010 Dec 28;5(12):e15245. doi: 10.1371/journal.pone.0015245. PLoS One. 2010. PMID: 21209946 Free PMC article.
-
Pathways of cellular proteostasis in aging and disease.J Cell Biol. 2018 Jan 2;217(1):51-63. doi: 10.1083/jcb.201709072. Epub 2017 Nov 10. J Cell Biol. 2018. PMID: 29127110 Free PMC article. Review.
-
Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease.Mol Neurodegener. 2012 May 14;7:20. doi: 10.1186/1750-1326-7-20. Mol Neurodegener. 2012. PMID: 22583646 Free PMC article.
-
Translation: screening for novel therapeutics with disease-relevant cell types derived from human stem cell models.Biol Psychiatry. 2014 Jun 15;75(12):952-60. doi: 10.1016/j.biopsych.2013.05.028. Epub 2013 Jul 19. Biol Psychiatry. 2014. PMID: 23876186 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical